Results 171 to 180 of about 35,706 (250)

Engineering macrophages for effective and safe targeting of CD47 cancer cells in the tumor microenvironment. [PDF]

J Immunother Cancer
Andón FT, Rosales Sánchez A, Pensado-López A, García-Campelo R, Takimoto CH.   +4 more
europepmc   +1 more source

CD47 wt Allele [PDF]

, 2020
openaire   +1 more source

Remodeling the Inflammatory Microenvironment: Nanomaterial‐Based Targeted Strategies for Systemic Lupus Erythematosus and Lupus Nephritis

Small Science, Volume 6, Issue 3, March 2026.
Current treatments for severe lupus nephritis are limited by side effects due to poor drug targeting. This review explores how smart nanomaterials—like liposomes and biomimetic carriers—can precisely deliver drugs to overactive immune cells and the kidneys. These nanotherapeutics enhance efficacy, reduce toxicity, and enable combination strategies. The
Cheng Zhou, Jiayi Li, Jian Zhang, Haifeng Wang, Haitao Lu, Shunlai Shang, Wenge Li   +6 more
wiley   +1 more source

Low-dose DOX-polygodial nanosystem modulates the CD47/CALR axis for safer triple negative breast cancer treatment. [PDF]

Nanoscale Adv
Emara HM, Youness RA, Manie TM, Abdelnaser A, Allam NK.   +4 more
europepmc   +1 more source

A Reproducible Workflow for Macrophage Membrane Isolation and Nanocore Selection Toward Bioinspired Nanoparticles Targeting Immunologically Cold Tumors

Small Methods, Volume 10, Issue 5, 9 March 2026.
A reproducible workflow is established for isolating macrophage membranes to enable the efficient preparation and characterization of membrane‐coated nanoparticles. By optimizing M2‐like nanovesicle stability and nanocore compatibility, this procedure advances the engineering of macrophage membrane‐coated nanoparticles with improved tumor targeting ...
Diana Peixoto, Patricia Diaz‐Rodriguez, Francisco Veiga, Angel Concheiro, Ana Cláudia Paiva‐Santos, João Conde, Carmen Alvarez‐Lorenzo   +6 more
wiley   +1 more source

CD47 blockade (ALX301) enhances immunoradiotherapy response in HPV negative head and neck squamous cell carcinoma. [PDF]

PLoS One
Monther A, Al-Msari R, Saddawi-Konefka R, Fassardi S, Tang C, Philips C, Sen P, Mohammadzadeh P, Decker K, Miyauchi S, Roy S, Jones R, Wu X, Gutkind S, Sharabi A, Califano J.   +15 more
europepmc   +1 more source

Silencing of CD47 and SIRPα by Polypurine reverse Hoogsteen hairpins to promote MCF-7 breast cancer cells death by PMA-differentiated THP-1 cells [PDF]

, 2016

core   +1 more source

Advances in Engineered Extracellular Vesicles for the Treatment of Atherosclerosis and Atherothrombosis – Next‐Generation Cardiovascular Nanomedicine

Small Structures, Volume 7, Issue 3, March 2026.
Exosomes (small extracellular vesicles) are nanosized vesicles produced naturally by living cells. They can be engineered by various techniques to deliver biologically active molecules to injury sites in atherosclerosis and atherothrombosis. Therefore, an exosome‐based multifunctional nanomedicine for the diagnosis, monitoring, and treatment of these ...
Tuan Huu Nguyen, Nhu Thao Huynh, Be'eri Niego, Christoph E. Hagemeyer, Rong Xu   +4 more
wiley   +1 more source

Drug Delivery Systems for Resiquimod to Control Myeloid‐Derived Suppressor Cells in Cancer Immunotherapy

WIREs Nanomedicine and Nanobiotechnology, Volume 18, Issue 2, March/April 2026.
Myeloid‐derived suppressor cells (MDSCs) are key contributors to cancer immunotherapy failure and major targets in new therapeutic strategies. We highlight therapeutic approaches to counteract their immunosuppressive functions and discuss recent efforts to optimize drug delivery for controlling MDSCs, focusing on resiquimod as a representative drug ...
Yanying He, Yoon Yeo
wiley   +1 more source

An oncolytic vaccinia virus encoding CD47 nanobody potentiates antitumor immunity in multiple myeloma. [PDF]

iScience
Pan L, Zhu X, Zhang J, Zhong Q, Wu H, Sun W, Xia Y, Wang S, Tong X.   +8 more
europepmc   +1 more source